The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Biden-era drug price negotiations that doubles down on actions they’ve resisted since the program began, Bloomberg Law’s Nyah Phengsitthy reports. The pushback was revealed in comments in response to the Centers for Medicare & Medicaid Services’ draft guidance for the third cycle of the drug price negotiation program. This next round round of talks is slated to begin in 2026 and target 15 additional drugs, the report notes. Publicly traded drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Pharma cos criticize Trump’s drug price negotiation plan, Bloomberg Law reports
- Johnson & Johnson submits sNDA to U.S FDA for CAPLYTA
- Nanobiotix announces regulatory harmonization, new patent for JNJ-1900
- Balanced Outlook on Johnson & Johnson: MedTech Growth vs. Pharmaceutical Challenges
- Truist biotech analyst holds an analyst/industry conference call